Ítem
Acceso Abierto

GLP-1 Analogues in the Neurobiology of Addiction

Mostrar el registro sencillo de la publicación
dc.creatorRodríguez-Quintana, Jesússpa
dc.creatorCalderon Ospina, Carlos Albertospa
dc.creatorRojas-Rodríguez, Luis Carlosspa
dc.creatorCarrillo-Vaca, Lilianaspa
dc.creatorForero-Cárdenas, Saraspa
dc.creatorTibaduiza-Arévalo, Lucía Catalinaspa
dc.creatorBarrera-Carreño, Samuelspa
dc.creatorOlaya-Bonilla, Santiago Arturospa
dc.creatorMarquez-Meneses, Juan Davidspa
dc.date.accessioned2025-07-21T16:44:30Z
dc.date.available2025-07-21T16:44:30Z
dc.date.created2025-06-01spa
dc.date.issued2025-06-01spa
dc.description.abstractGlucagon-like peptide-1 receptor agonists, originally developed for the treatment of metabolic disorders, have recently emerged as promising candidates for the management of substance use disorders. This review synthesizes preclinical, clinical, and translational evidence on the effects of glucagon-like peptide-1 receptor agonists across addiction models involving alcohol, nicotine, psychostimulants, and opioids. In animal studies, glucagon-like peptide-1 receptor agonists consistently reduce drug intake, attenuate dopamine release in reward circuits, and decrease relapse-like behavior. Clinical and observational studies provide preliminary support for these findings, particularly among individuals with comorbid obesity or insulin resistance. However, several translational barriers remain, including limited blood–brain barrier penetration, species differences in pharmacokinetics, and variability in treatment response due to genetic and metabolic factors. Ethical considerations and methodological heterogeneity further complicate clinical translation. Future directions include the development of central nervous system penetrant analogues, personalized medicine approaches incorporating pharmacogenomics, and rigorously designed trials in diverse populations. Glucagon-like peptide-1 receptor agonists may offer a novel therapeutic strategy that addresses both metabolic and neuropsychiatric dimensions of addiction, warranting further investigation to define their role in the evolving landscape of substance use disorder treatment.eng
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.3390/ijms26115338spa
dc.identifier.issn1661-6596spa
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/46075
dc.language.isoengspa
dc.publisherMDPIspa
dc.relation.ispartofInternational Journal of Molecular Science 2025, 26(11), 5338spa
dc.relation.urihttps://www.mdpi.com/1422-0067/26/11/5338spa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accesoAbierto (Texto Completo)spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.sourceInternational Journal of Molecular Sciencespa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordQuímica orgánicaeng
dc.subject.keywordGlucagon-like peptide-1 receptor agonistseng
dc.subject.keywordSubstance-related disorderseng
dc.subject.keywordBrain–gut axiseng
dc.subject.keywordAlcoholismeng
dc.subject.keywordTobacco use disordereng
dc.subject.keywordCocaine-related disorderseng
dc.subject.keywordAmphetamine-related disorderseng
dc.subject.keywordOpioid-related disorderseng
dc.subject.keywordBlood–brain barriereng
dc.subject.keywordTranslational researcheng
dc.subject.keywordBiomedicaleng
dc.titleGLP-1 Analogues in the Neurobiology of Addictionspa
dc.typearticlespa
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersionspa
dc.type.spaArtículo de revisiónspa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
GLP-1_Analogues_in_the_Neurobiology_of_Addiction.pdf
Tamaño:
1.14 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos